Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Cytoreductive nephrectomy for mRCC treated with immune checkpoint inhibitors or targeted therapy

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 18.02.20
Views: 411

Dr Ziad Bakouny - Dana-Farber Cancer Institute, Boston, USA

Dr Ziad Bakouny speaks to ecancer at the 2020 ASCO GU meeting at San Francisco about a propensity score-based analysis into cytoreductive nephrectomy for mRCC (metastatic renal cell carcinoma) treated with immune checkpoint inhibitors or targeted therapy.

He reports that cytoreductive nephrectomy was still associated with a survival benefit with these immune checkpoint inhibitors.

Dr Bakouny concludes by suggesting that patients with better risk disease and lower metastatic burden can still benefit from cytoreductive nephrectomy.

Related videos

follow us

Donate to ecancer

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation